CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1 enrolled
Drug / intervention
Ranibizumabdrug
Likely dose
Ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00384449
NCT00384449Phase 3Completed
CompareCT.gov

The Use of a VEGF Inhibitor (Lucentis) in Refractory Macular Edema Due to Eales' Disease

Oregon Health and Science University·interventional·Posted Oct 6, 2006·Updated Jun 11, 2019

In Brief

A Phase 3 clinical trial evaluating Ranibizumab for Eales' Disease. Completed, enrolled 1 participant across 1 site.

Detailed Summary

The primary objective of this protocol is to look at whether Lucentis (ranibizumab) is safe and effective when used for macular edema (retinal swelling) due to Eales' disease. The secondary objective is to see if macular edema comes back within three months after the last dose of study drug is given.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEales' Disease
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 6, 2006
Enrollment StartOct 1, 2006
Primary CompletionApr 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 19.7 years ago

Interventions

Ranibizumabdrug

Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months